Teleflex (NYSE:TFX) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Teleflex from “hold” to “sell,” even though the broader analyst view remains mixed with an overall average rating of “hold” and a consensus price target of $142.86.
• Teleflex beat first-quarter expectations, reporting EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, with revenue up 32.3% year over year.
• Despite the quarterly beat, the company’s FY2026 EPS guidance of $6.25 to $6.55 came in below market expectations, which may temper enthusiasm for the stock.

Teleflex (NYSE:TFX - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

A number of other analysts have also recently weighed in on TFX. Raymond James Financial reaffirmed an "outperform" rating and set a $150.00 price objective on shares of Teleflex in a research report on Friday. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Teleflex in a research report on Friday, March 27th. Royal Bank Of Canada raised Teleflex from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $135.00 to $155.00 in a research report on Friday. Mizuho set a $140.00 price objective on Teleflex in a research report on Friday. Finally, Bank of America raised Teleflex from an "underperform" rating to a "neutral" rating and set a $135.00 price objective for the company in a research report on Monday, April 13th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teleflex currently has an average rating of "Hold" and an average target price of $142.86.

Teleflex Stock Up 1.1%

Teleflex stock opened at $133.17 on Friday. Teleflex has a twelve month low of $100.18 and a twelve month high of $139.67. The stock has a 50 day moving average of $119.44 and a two-hundred day moving average of $116.73. The company has a current ratio of 2.55, a quick ratio of 2.01 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $5.89 billion, a price-to-earnings ratio of -5.84, a PEG ratio of 0.95 and a beta of 0.82.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts' consensus estimates of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The company had revenue of $548.30 million during the quarter, compared to analysts' expectations of $536.91 million. During the same period last year, the firm earned $1.44 EPS. The firm's revenue for the quarter was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts expect that Teleflex will post 6.75 earnings per share for the current year.

Hedge Funds Weigh In On Teleflex

A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC raised its stake in shares of Teleflex by 2.0% during the 4th quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company's stock worth $518,196,000 after buying an additional 84,754 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Teleflex by 478.1% during the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company's stock worth $287,603,000 after buying an additional 1,956,811 shares in the last quarter. State Street Corp raised its stake in shares of Teleflex by 1.5% during the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company's stock worth $180,470,000 after buying an additional 22,111 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Teleflex by 0.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company's stock worth $152,630,000 after buying an additional 5,051 shares in the last quarter. Finally, Cooke & Bieler LP raised its stake in shares of Teleflex by 1.2% during the 3rd quarter. Cooke & Bieler LP now owns 1,220,637 shares of the medical technology company's stock worth $149,357,000 after buying an additional 14,673 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title
• Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title
• Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title
• Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title
• Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.